Arcus Biosciences Advances Casdatifan Phase 3 Trials
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 18 2025
0mins
Should l Buy RCUS?
Arcus Biosciences Inc. shares rose by 7.92% as the stock reached a 20-day high amid broader market declines.
The company is advancing its PEAK-1 Phase 3 trial for casdatifan, aiming to establish it as the standard of care for clear cell renal cell carcinoma. Arcus plans to present updated progression-free survival data from the ARC-20 study at a medical conference in February 2026, alongside its financial stability with approximately $1 billion in cash to support operations until at least 2028.
This advancement in clinical trials and the financial backing positions Arcus favorably in the competitive landscape of oncology, potentially attracting more investor interest as they continue to develop innovative treatments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RCUS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RCUS
Wall Street analysts forecast RCUS stock price to rise
9 Analyst Rating
6 Buy
3 Hold
0 Sell
Moderate Buy
Current: 20.250
Low
14.00
Averages
27.44
High
44.00
Current: 20.250
Low
14.00
Averages
27.44
High
44.00
About RCUS
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Arcus Biosciences Grants Stock Options to New Employees
- Stock Option Grant: Arcus Biosciences has granted stock options totaling 7,050 shares to two new employees at an exercise price of $21.41 per share, based on the closing price on March 23, 2026, reflecting the company's commitment to incentivizing new talent.
- Restricted Stock Units: In addition, the company awarded 3,550 shares in restricted stock units, aimed at further attracting and retaining talent, thereby enhancing team stability and execution capabilities.
- Incentive Plan Context: The stock grants are made under the company's 2020 Inducement Plan, approved by the Board of Directors, complying with the NYSE Listed Company Manual Rule 303A.08's
See More
Arcus Biosciences Grants Stock Options to New Employees
- Stock Option Grant: Arcus Biosciences has granted stock options totaling 17,050 shares to two new employees at an exercise price of $23.43, reflecting the closing price on March 9, 2026, indicating the company's commitment to incentivizing new talent.
- Restricted Stock Units: In addition, the company awarded 8,550 shares in restricted stock units, further enhancing its long-term incentive mechanisms aimed at attracting and retaining key personnel to support its growth trajectory.
- Inducement Plan Context: The stock grants were made under the company's 2020 Inducement Plan, which was approved in January 2020, aligning with the
See More
Arcus (RCUS) Q4 2025 Earnings Call Transcript
See More
Arcus Biosciences Q4 Earnings Beat Expectations
- Earnings Highlights: Arcus Biosciences reported a Q4 GAAP EPS of -$0.89, beating expectations by $0.14, indicating efforts in cost management despite still posting a negative profit.
- Revenue Performance: The company generated $33 million in revenue for Q4, an 8.3% year-over-year decline, yet exceeded market expectations by $8.06 million, suggesting a resilient market demand amid challenges.
- Market Reaction: Despite the revenue drop, Arcus showcased its product pipeline, particularly the progress of Casdatifan, at the J.P. Morgan Healthcare Conference, which may attract investor interest.
- Research Developments: The late-stage study for the anti-TIGIT cancer drug in collaboration with Gilead has been halted, a decision that could impact future R&D directions and funding allocations.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, indicating a shift in market sentiment that could influence investor decisions and market trends.
- Overview of Updates: While specific upgrades and downgrades are not detailed, the overall rating changes may prompt investors to reassess their positions, potentially affecting trading volumes and price fluctuations of the related stocks.
- Expected Market Reaction: Analyst rating adjustments typically elicit immediate market responses, and investors should monitor these changes to seize potential investment opportunities or mitigate risks.
- Source of Information: This information is provided by Benzinga, highlighting the significance of analyst ratings in investment decisions, and investors are encouraged to regularly check the analyst ratings page for the latest updates.
See More
Arcus Biosciences Grants Stock Options to Employees
- Stock Option Grant: Arcus Biosciences granted stock options totaling 16,650 shares to three new employees at an exercise price of $22.13 per share, reflecting the company's commitment to talent retention and motivation.
- Restricted Stock Units: The company also awarded 8,400 shares in restricted stock units, aimed at enhancing employee loyalty and long-term incentives, thereby promoting overall company growth.
- Inducement Plan Context: These equity awards were granted under the company's 2020 Inducement Plan, which was approved by the Board in January 2020, aligning with the NYSE's
See More
Arcus Biosciences Grants Stock Options to New Employees
- Stock Option Grant: Arcus Biosciences has granted stock options totaling 7,050 shares to two new employees at an exercise price of $21.41 per share, based on the closing price on March 23, 2026, reflecting the company's commitment to incentivizing new talent.
- Restricted Stock Units: In addition, the company awarded 3,550 shares in restricted stock units, aimed at further attracting and retaining talent, thereby enhancing team stability and execution capabilities.
- Incentive Plan Context: The stock grants are made under the company's 2020 Inducement Plan, approved by the Board of Directors, complying with the NYSE Listed Company Manual Rule 303A.08's
See More
Arcus Biosciences Grants Stock Options to New Employees
- Stock Option Grant: Arcus Biosciences has granted stock options totaling 17,050 shares to two new employees at an exercise price of $23.43, reflecting the closing price on March 9, 2026, indicating the company's commitment to incentivizing new talent.
- Restricted Stock Units: In addition, the company awarded 8,550 shares in restricted stock units, further enhancing its long-term incentive mechanisms aimed at attracting and retaining key personnel to support its growth trajectory.
- Inducement Plan Context: The stock grants were made under the company's 2020 Inducement Plan, which was approved in January 2020, aligning with the
See More
Arcus (RCUS) Q4 2025 Earnings Call Transcript
See More
Arcus Biosciences Q4 Earnings Beat Expectations
- Earnings Highlights: Arcus Biosciences reported a Q4 GAAP EPS of -$0.89, beating expectations by $0.14, indicating efforts in cost management despite still posting a negative profit.
- Revenue Performance: The company generated $33 million in revenue for Q4, an 8.3% year-over-year decline, yet exceeded market expectations by $8.06 million, suggesting a resilient market demand amid challenges.
- Market Reaction: Despite the revenue drop, Arcus showcased its product pipeline, particularly the progress of Casdatifan, at the J.P. Morgan Healthcare Conference, which may attract investor interest.
- Research Developments: The late-stage study for the anti-TIGIT cancer drug in collaboration with Gilead has been halted, a decision that could impact future R&D directions and funding allocations.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, indicating a shift in market sentiment that could influence investor decisions and market trends.
- Overview of Updates: While specific upgrades and downgrades are not detailed, the overall rating changes may prompt investors to reassess their positions, potentially affecting trading volumes and price fluctuations of the related stocks.
- Expected Market Reaction: Analyst rating adjustments typically elicit immediate market responses, and investors should monitor these changes to seize potential investment opportunities or mitigate risks.
- Source of Information: This information is provided by Benzinga, highlighting the significance of analyst ratings in investment decisions, and investors are encouraged to regularly check the analyst ratings page for the latest updates.
See More
Arcus Biosciences Grants Stock Options to Employees
- Stock Option Grant: Arcus Biosciences granted stock options totaling 16,650 shares to three new employees at an exercise price of $22.13 per share, reflecting the company's commitment to talent retention and motivation.
- Restricted Stock Units: The company also awarded 8,400 shares in restricted stock units, aimed at enhancing employee loyalty and long-term incentives, thereby promoting overall company growth.
- Inducement Plan Context: These equity awards were granted under the company's 2020 Inducement Plan, which was approved by the Board in January 2020, aligning with the NYSE's
See More
